Neulasta

Amgen pleads guilty in False Claims Act case

Amgen "marketed the spread" between the price practices pay for Aranesp and that patients pay as a means of driving sales — to the point of having speakers tell physicians that they could make a million more each year by prescribing the Amgen anemia drug over its competitor, Procrit.